Download PDF
CC BY 4.0 · TH Open 2018; 02(04): e420-e427
DOI: 10.1055/s-0038-1676356
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Choice of Renal Function Estimator Influences Adverse Outcomes with Dabigatran Etexilate in Patients with Atrial Fibrillation

Bryan H. Simpson
1   School of Pharmacy, University of Otago, Dunedin, New Zealand
,
David M. Reith
2   Dunedin Medical School, University of Otago, Dunedin, New Zealand
,
Natalie J. Medlicott
1   School of Pharmacy, University of Otago, Dunedin, New Zealand
,
Alesha J. Smith
1   School of Pharmacy, University of Otago, Dunedin, New Zealand
› Author Affiliations
Further Information

Publication History

17 April 2018

15 October 2018

Publication Date:
10 December 2018 (online)

   Permissions and Reprints

Abstract

Background Clinical significance of dosing dabigatran with different estimates of renal function for treatment of atrial fibrillation (AF) is unknown. Renal function is routinely estimated by the chronic kidney disease epidemiology initiative equation (CKD-EPI) and used to guide dosing. The aim of this study was to investigate the risk of adverse outcomes for patients with AF when different estimators of renal function are used.

Material and Methods AF patient data were extracted from national administrative databases. Renal function was estimated using Cockcroft–Gault, CKD-EPI, and CKD-EPI adjusted for body surface area (CKD-EPI-BSA). Outcomes of cerebrovascular accident (CVA), systemic embolism (SE), and hemorrhage were extracted.

Results In total, 2,425 patients were identified, of which there were hospitalizations for 138 (5.7%) hemorrhagic events, 45 (1.9%) CVA/SE, and 33 (1.4%) unspecified CVA. The level of agreement between Cockcroft–Gault with CKD-EPI and CKD-EPI-BSA yielded a weighted kappa statistic of 0.47 and 0.71, respectively. CKD-EPI and CKD-EPI-BSA significantly overestimated renal function in elderly patients resulting in higher recommended doses compared with Cockcroft–Gault. The hazard ratio for a hemorrhagic event was 2.32 (95% confidence interval, 1.22–4.42; p = 0.01) when a high dose was given compared with normal dose, based on Cockcroft–Gault.

Conclusion Both CKD-EPI and CKD-EPI-BSA equations significantly overestimated renal function in the elderly population compared with the Cockcroft–Gault equation. This may lead to dose selection errors for dabigatran, particularly for those with severe impairment, increasing the risk of adverse outcome. Hence, CKD-EPI and CKD-EPI-BSA equations should not be substituted for the Cockcroft–Gault equation in the elderly for the purpose of renal dosage adjustments.

Keywords

dabigatran etexilate - hemorrhage - cerebrovascular accident - systemic embolism - renal function

Supplementary Material

 

  • References

  • 1 Helldén A, Odar-Cederlöf I, Nilsson G. , et al. Renal function estimations and dose recommendations for dabigatran, gabapentin and valaciclovir: a data simulation study focused on the elderly. BMJ Open 2013; 3 (04) e002686
    CrossrefPubMedGoogle Scholar
  • 2 Dowling TC, Wang E-S, Ferrucci L, Sorkin JD. Glomerular filtration rate equations overestimate creatinine clearance in older individuals enrolled in the Baltimore Longitudinal Study on Aging: impact on renal drug dosing. Pharmacotherapy 2013; 33 (09) 912-921
    CrossrefPubMedGoogle Scholar
  • 3 Hudson JQ, Bean JR, Burger CF, Stephens AK, McFarland MS. Estimated glomerular filtration rate leads to higher drug dose recommendations in the elderly compared with creatinine clearance. Int J Clin Pract 2015; 69 (03) 313-320
    CrossrefPubMedGoogle Scholar
  • 4 Maccallum PK, Mathur R, Hull SA. , et al. Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation: a cross-sectional study. BMJ Open 2013; 3 (09) e003343
    CrossrefPubMedGoogle Scholar
  • 5 Manzano-Fernández S, Andreu-Cayuelas JM, Marín F. , et al. Comparison of estimated glomerular filtration rate equations for dosing new oral anticoagulants in patients with atrial fibrillation. Rev Esp Cardiol (Engl Ed) 2015; 68 (06) 497-504
    CrossrefPubMedGoogle Scholar
  • 6 Pérez Cabeza AI, Chinchurreta Capote PA, González Correa JA. , et al. Discrepancies between the use of MDRD-4 IDMS and CKD-EPI equations, instead of the Cockcroft-Gault equation, in the determination of the dosage of direct oral anticoagulants in patients with non-valvular atrial fibrillation. Med Clin (Barc) 2018; 150 (03) 85-91
    CrossrefPubMedGoogle Scholar
  • 7 Ezekowitz MD, Connolly S, Parekh A. , et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 2009; 157 (05) 805-810 , 810.e1–810.e2
    CrossrefPubMedGoogle Scholar
  • 8 Steinberg BA, Shrader P, Thomas L. , et al; ORBIT-AF Investigators and Patients. Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: The ORBIT-AF II Registry. J Am Coll Cardiol 2016; 68 (24) 2597-2604
    CrossrefPubMedGoogle Scholar
  • 9 Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA. Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol 2017; 69 (23) 2779-2790
    CrossrefPubMedGoogle Scholar
  • 10 Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16 (01) 31-41
    CrossrefPubMedGoogle Scholar
  • 11 Levey AS, Stevens LA, Schmid CH. , et al; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150 (09) 604-612
    CrossrefPubMedGoogle Scholar
  • 12 Michels WM, Grootendorst DC, Verduijn M, Elliott EG, Dekker FW, Krediet RT. Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. Clin J Am Soc Nephrol 2010; 5 (06) 1003-1009
    CrossrefPubMedGoogle Scholar
  • 13 U.S. Department of Health and Human Services. Guidance for Industry: Pharmacokinetics in Patients with Impaired Renal Function—Study Design, Data Analysis, and Impact on Dosing and Labeling. Silver Spring, MD: US Food and Drug Administration; 1998
  • 14 European Medicines Agency. Guideline on the Evaluation of the Pharmacokinetics of Medicinal Products in Patients with Decreased Renal Function. Committee for Medicinal Products for Human Use (CHMP); 2015
  • 15 Johnson DW, Jones GRD, Mathew TH. , et al; Australasian Creatinine Consensus Working Group. Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: new developments and revised recommendations. Med J Aust 2012; 197 (04) 224-225
    CrossrefPubMedGoogle Scholar
  • 16 Howey OK, Chin PK. Usage of renal function equations to guide prescribing in general medicine. N Z Med J 2013; 126 (1383): 97-99
    PubMedGoogle Scholar
  • 17 Boehringer Ingelheim (N.Z.) Limited. Pradaxa: New Zealand Datasheet (2017); Available at: http://www.medsafe.govt.nz/profs/datasheet/p/Pradaxacap.pdf . Accessed November 2017
    PubMed
  • 18 January CT, Wann LS, Alpert JS. , et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64 (21) e1 –e76
    CrossrefPubMedGoogle Scholar
  • 19 Steffel J, Verhamme P, Potpara TS. , et al; ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018; 39 (16) 1330-1393
    CrossrefPubMedGoogle Scholar
  • 20 Jones GRD. Estimating renal function for drug dosing decisions. Clin Biochem Rev 2011; 32 (02) 81-88
    PubMedGoogle Scholar
  • 21 Chin PKL, Wright DFB, Florkowski CM. Letter by Chin et al regarding article, “Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial analysis”. Circulation 2014; 130 (22) e194
    PubMedGoogle Scholar
  • 22 Best Practice. Decision Support for Health Professionals. Available at: http://www.bestpractice.net.nz/ . Accessed March 12, 2018
    PubMed
  • 23 New Zealand Ministry of Health. Pharmaceutical Collection. Wellington: Ministry of Health; 2016
  • 24 Committee for Human Medicinal Products (CHMP). Adequacy of guidance on the elderly regarding medicinal products for human use. London: European Medicines Agency; 2011 [cited October 2017]. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500049541.pdf
  • 25 New Zealand Ministry of Health, National Minimum Dataset (Hospital Events) data dictionary. Wellington: Ministry of Health; 2015
  • 26 The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM). 6th ed. Lidcombe, NSW: National Centre for Classification in Health; 2008
  • 27 Hijazi Z, Wallentin L. Renal function in atrial fibrillation: a multifaceted dilemma. Circulation 2016; 134 (01) 48-51
    CrossrefPubMedGoogle Scholar
  • 28 Hijazi Z, Hohnloser SH, Oldgren J. , et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation 2014; 129 (09) 961-970
    CrossrefPubMedGoogle Scholar
  • 29 Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985; 33 (04) 278-285
    CrossrefPubMedGoogle Scholar
  • 30 Graham DJ, Reichman ME, Wernecke M. , et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015; 131 (02) 157-164
    CrossrefPubMedGoogle Scholar
  • 31 Arnason T, Wells PS, van Walraven C, Forster AJ. Accuracy of coding for possible warfarin complications in hospital discharge abstracts. Thromb Res 2006; 118 (02) 253-262
    CrossrefPubMedGoogle Scholar
  • 32 Woodfield R, Grant I, Sudlow CL. ; UK Biobank Stroke Outcomes Group; UK Biobank Follow-Up and Outcomes Working Group. Accuracy of electronic health record data for identifying stroke cases in large-scale epidemiological studies: A systematic review from the UK biobank stroke outcomes group. PLoS One 2015; 10 (10) e0140533
    CrossrefPubMedGoogle Scholar
  • 33 Simpson B, Reith D, Medlicott N, Smith A. Utilisation of New Zealand primary care electronic data to guide clinical decision support system design—a retrospective cohort for dabigatran. Clin Ther 2017; 39 (08) e7
    CrossrefPubMedGoogle Scholar